British Journal of Urology · 2006 · 24 citations · 10 references
MedicineOncologySurgeryChemotherapySurgical OncologyUrologic OncologyBladder CancerBladder SurgeryUrogenital Oncology SurgeryUrologic InterventionsUrologic Oncology SurgeryBladder Tumor ExcisionBladder Tumor SurgeryIntravesical ChemotherapyMitomycin C ProphylaxisMitomycin C TherapyMitomycin C TreatmentPreoperative ProphylaxisSerious Adverse Events
OBJECTIVE: To assess the feasibility and safety of administering intravesical mitomycin C in theatre immediately after transurethral resection of bladder tumour (TURBT). PATIENTS AND METHODS: A protocol was developed to allow the safe administration of mitomycin C in theatre immediately after TURBT. Over a 32-month period all patients not excluded by the protocol were given mitomycin C in theatre after TURBT, and any adverse events reported. RESULTS: In all, 177 instillations were carried out; there were two minor patient-related complications, and no staff-related adverse events. CONCLUSION: The immediate administration of mitomycin C in theatre after TURBT is feasible and safe for patients and staff. It provides the earliest and surest prophylaxis against tumour cell re-implantation at TURBT.
10
Willem Oosterlinck, Karl H. Kurth, Fritz H. Schröder et al. · The Journal of Urology · 1993 · 367 citations
Ch. Bouffioux, K. H. Kurth, A. Bono et al. · The Journal of Urology · 1995 · 175 citations